2025中国药企年度观察:BD交易+赴港上市双赛道狂奔

药融圈
Jan 01

当4月深耕肿瘤领域的劲方医药-B登陆港股募资35亿港元,当7月专注ADC药物研发的映恩生物-B完成港股IPO募资33亿港元;当三生制药在2025年5月将PD-1/VEGF双抗SSGJ-707以超60亿美元总交易额授权辉瑞,刷新国内双抗出海纪录;当恒瑞医药于2025年7月通过创新药组合授权交易,从GSK斩获5亿美元首付款,总潜在交易金额更是高达125亿美元——回顾 2025年,中国医药行业呈现出BD...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10